Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 441
- Registration Number
- NCT00454740
Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity
Completed
- Conditions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- University of L'Aquila
- Registration Number
- NCT00441428
- Locations
- 🇮🇹
University of L'Aquila, L'Aquila, Abruzzo, Italy
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 132
- Registration Number
- NCT00431041
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-25
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 246
- Registration Number
- NCT00368706
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 643
- Registration Number
- NCT00337558
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 398
- Registration Number
- NCT00333112
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189800
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath